Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?

Journal of Extra-Corporeal Technology

Volumn 37, Issue 2, 2005, Pages 153-156

  Baker, Mya S ^a,b   Skoyles, Julian R ^a   Shajar, Matt ^a   Skinner, Henry ^a   Richens, David ^a   Mitchell, Ian M ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bio electrical impedence; Cardiopulmonary bypass; Hemotasis; Heparin; Lean body mass; Obesity; Protamine

Indexed keywords

FENTANYL; HEPARIN; PROPOFOL; PROTAMINE;

ADULT; AGED; ANESTHESIA; ARTICLE; BLOOD CLOTTING TIME; BODY FAT; BODY MASS; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; DOSE CALCULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FEMALE; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMPEDANCE; INSULIN DEPENDENT DIABETES MELLITUS; LEAN BODY WEIGHT; MALE; OBESITY; STATISTICAL ANALYSIS; VASECTOMY;

EID: 22044434962     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bennet N, Dodd T, Flatley J, Freeth S, Bolling K. Health Survey for England 1993. London: HMSO; 1995.
2. Centre for Obesity Surgery St James's Hospital Leeds. UK www. obesitysurgery.org.uk/: Obesity: The Disease
3. Chemoyl G. Clinical Pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet. 1993;25:103-14.
4. Trossaert M, Gaiilard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence if anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass. Br J Haematol. 1998;101:653-5.
5. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse effects after protamine administration in patients undergoing cardiopulmonary bypass: risk predictors of under-reporting. J Clin Epidemiol. 1998;51:1-10.
6. Ionue S, Miyashita T, Kuro M. A case of twice catastrophic pulmonary vasoconstriction- type shock induced with protamine sulphate. Masui. 1997;46:987-90.
7. Tevaearai HT, Jegger D, Mueller XM, Horisberger J, von Segesser LK. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine. Thorac Cardiovasc Surg. 1998;46: 303-4.
8. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994;26:292-307.
9. Brown ME, Gallagher JM, Armitage JM. The use of Human antithrombin III concentrate for treatment of heparin resistance during cardiopulmonary bypass. J Extra Corpor Technol. 2000;32:75-8.
10. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin: an experimental study on dogs and humans. Acta Med Scand. 1963;173:619-30.